Can I Take Turmeric / Curcumin with Egrifta (Tesamorelin)?
At a glance
- Drug / Egrifta SV (tesamorelin), 1.4 mg subcutaneously once daily
- Supplement / Turmeric or curcumin, sometimes sold with piperine (black pepper extract)
- Curcuminoids vs CYP enzymes / No meaningful change in probe-drug kinetics in a small, short-term human crossover study [1]
- Piperine / Raised propranolol, theophylline and phenytoin levels in human studies [3][4]
- Turmeric's main serious risk / Rare but documented liver injury, including one death in a US case series [2]
- Egrifta SV label's interaction section / Covers CYP450-metabolized drugs and glucocorticoid replacement, not turmeric [5]
- Monitoring the label asks for / IGF-1 and glucose during treatment [5]
What the Egrifta SV Label Says About Interactions
Egrifta SV is tesamorelin 1.4 mg (0.35 mL of the reconstituted solution) injected subcutaneously into the abdomen once daily [5]. Its drug interaction section has two parts. The first covers drugs metabolized by cytochrome P450 enzymes: growth hormone may alter the clearance of compounds handled by CYP450 liver enzymes, with corticosteroids, sex steroids, anticonvulsants and cyclosporine named as examples, and the label asks prescribers to monitor when Egrifta SV is given with them [5]. Co-administration with simvastatin had no significant impact on its pharmacokinetics, while ritonavir AUC decreased by 9% [5]. The second part covers glucocorticoid replacement: growth hormone inhibits 11-beta-HSD1, the enzyme required to convert cortisone to its active metabolite cortisol, and people receiving cortisone acetate or prednisone as glucocorticoid replacement for previously diagnosed hypoadrenalism may need higher maintenance or stress doses after starting Egrifta SV [5]. Turmeric and curcumin are not named anywhere in that section.
Does Curcumin Change How Tesamorelin Is Handled?
Tesamorelin is a synthetic analog of human growth hormone-releasing factor, a 44-amino-acid peptide that stimulates the pituitary to release the body's own growth hormone [5]. Per the label, absolute bioavailability was under 4% in healthy adults given a 2 mg dose of the original 1 mg/vial formulation, the elimination half-life was about 8 minutes after Egrifta SV 1.4 mg, and no formal human metabolism studies have been performed [5]. Curcumin, by contrast, is rapidly glucuronidated in the liver and intestinal wall, and after oral intake plasma curcuminoids are mostly conjugated, with free curcumin often below assay detection limits [6][1].
The human data that speak most directly to a curcumin-drug interaction come from a randomized, placebo-controlled six-way crossover in 8 healthy volunteers. They took a standardized curcuminoid/piperine preparation (4 g curcuminoids plus 24 mg piperine) four times over 2 days, then probe drugs for CYP3A (midazolam), CYP2C9 (flurbiprofen) and UGT and SULT (paracetamol). Curcuminoid treatment produced no meaningful changes in Cmax, AUC, clearance, half-life or metabolite levels of any of the three probes, and no change in midazolam sedation or EEG effect [1]. Earlier laboratory work had predicted inhibition of those enzymes; in the volunteers, unconjugated curcuminoid concentrations stayed below assay detection [1]. That is short-term use in eight people, and none of the probes was tesamorelin.
Piperine Is the Part That Moves Other Drugs
Some curcumin products contain piperine, and piperine itself changes drug levels in humans. In a crossover study, 20 mg piperine daily for 7 days raised propranolol (40 mg) and theophylline (150 mg) exposure in 6 healthy subjects per group [3]. In 20 people with epilepsy taking phenytoin 150 or 200 mg twice daily, a single 20 mg dose of piperine significantly increased phenytoin AUC over 12 hours and Cmax [4].
How much piperine boosts curcumin is disputed. A 1998 study of 2 g curcumin with 20 mg piperine reported a 2,000% increase in bioavailability in humans [6], but later work with 4 g curcuminoids plus 24 mg piperine found free curcuminoids below detection [1], and a 2026 USP review reports that piperine at typical product doses of about 5 to 20 mg did not meaningfully change free or total curcuminoid levels in independent analyses [7]. Three of the 7 tested products in the US liver-injury series contained piperine, and whether piperine itself makes liver injury more likely is unproven [2][7].
Turmeric's Liver Risk Stands on Its Own
The US Drug-Induced Liver Injury Network published 10 adjudicated turmeric cases enrolled between 2004 and 2022. Eight were women, median age was 56, injury was hepatocellular in 9 and mixed in 1, 5 patients were hospitalized, 1 died of acute liver failure, latency was 1 to 4 months, and 7 of 10 carried HLA-B*35:01 (allele frequency 0.450 versus 0.056 to 0.069 in controls) [2]. Italian phytovigilance described 7 Tuscan cases of acute hepatitis, all associated with high-bioavailability, high-dose curcumin or curcuminoid products, with positive dechallenge in most. A review found 23 additional published cases, most of them in people taking at least one other medicine, with positive dechallenge in 16 [8]. AASLD practice guidance lists turmeric/curcumin as producing a hepatocellular pattern with recovery expected [9], and the 2026 USP review recommends a label caution about rare liver problems [7].
Set against that, a meta-analysis of 31 randomized trials of turmeric/curcumin found average ALT fell 4.09 U/L and AST 3.81 U/L versus control, with no change in GGT, on low- or very-low-quality evidence that the authors said does not ensure clinical benefit [10].
IGF-1 and Glucose: What the Label Watches During Egrifta SV Treatment
The Egrifta SV label directs prescribers to monitor IGF-1 during therapy because tesamorelin raises it. Among patients treated for 26 weeks, 47% had IGF-1 above 2 standard deviation scores and 36% above 3 SDS; at 52 weeks the figures were 34% and 23%, and the label suggests considering discontinuation with persistent elevations above 3 SDS, particularly if the fat-loss response is not robust [5]. The label also directs evaluation of glucose before and during treatment, because HbA1c of 6.5% or higher developed in 5% of tesamorelin patients versus 1% on placebo by week 26 (hazard ratio 3.3, 95% CI 1.4 to 9.6) [5].
Putting It Together
The probe-drug study did not test tesamorelin, so it does not show whether turmeric or piperine changes tesamorelin levels. The documented concerns are turmeric-associated liver injury, with a latency of 1 to 4 months in the US cases [2], and, for products that contain piperine, piperine's demonstrated ability to raise levels of some other drugs [3][4].
Frequently asked questions
Can I take turmeric while on Egrifta (tesamorelin)?
Does curcumin inhibit CYP3A4?
Does black pepper extract in a curcumin supplement matter?
Can turmeric cause liver injury?
Does curcumin affect IGF-1 or blood sugar on Egrifta?
Is curcumin a blood thinner?
References
Show all 13 referencesHide references
- Volak LP, Hanley MJ, Masse G, Hazarika S, Harmatz JS, Badmaev V, et al. Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2013;75(2):450-62.
- Halegoua-DeMarzio D, Navarro V, Ahmad J, Avula B, Barnhart H, Barritt AS, et al. Liver Injury Associated with Turmeric-A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN]. Am J Med. 2023;136(2):200-206.
- Bano G, Raina RK, Zutshi U, Bedi KL, Johri RK, Sharma SC. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. Eur J Clin Pharmacol. 1991;41(6):615-7.
- Pattanaik S, Hota D, Prabhakar S, Kharbanda P, Pandhi P. Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy. Phytother Res. 2006;20(8):683-6.
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353-6.
- Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP - PMC.
- Lombardi N, Crescioli G, Maggini V, Ippoliti I, Menniti-Ippolito F, Gallo E, et al. Acute liver injury following turmeric use in Tuscany: An analysis of the Italian Phytovigilance database and systematic review of case reports. Br J Clin Pharmacol. 2021;87(3):741-753.
- AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury - PMC.
- Dehzad MJ, Ghalandari H, Amini MR, Askarpour M. Effects of curcumin/turmeric supplementation on liver function in adults: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. Complement Ther Med. 2023;74:102952.
- Srivastava KC, Bordia A, Verma SK. Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prostaglandins Leukot Essent Fatty Acids. 1995;52(4):223-7.
- Liu AC, Zhao LX, Lou HX. Curcumin alters the pharmacokinetics of warfarin and clopidogrel in Wistar rats but has no effect on anticoagulation or antiplatelet aggregation. Planta Med. 2013;79(11):971-7.
- Bahramsoltani R, Rahimi R, Farzaei MH. Pharmacokinetic interactions of curcuminoids with conventional drugs: A review. J Ethnopharmacol. 2017;209:1-12.